The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion

Bromodomain and extraterminal domain (BET) proteins have emerged as therapeutic targets in multiple cancers, including the most common primary adult brain tumor glioblastoma (GBM). Although several BET inhibitors have entered clinical trials, few are brain penetrant. We have generated UM-002, a nove...

Descripción completa

Detalles Bibliográficos
Autores principales: Jermakowicz, Anna M., Rybin, Matthew J., Suter, Robert K., Sarkaria, Jann N., Zeier, Zane, Feng, Yangbo, Ayad, Nagi G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642539/
https://www.ncbi.nlm.nih.gov/pubmed/34862404
http://dx.doi.org/10.1038/s41598-021-02584-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642539/
https://www.ncbi.nlm.nih.gov/pubmed/34862404
http://dx.doi.org/10.1038/s41598-021-02584-6

Ejemplares similares